INS and diabetes mellitus: Compared to DM model group, low-dose PAOS or glibenclamide treatment were lower by 15.7%, 41.7% for FBG (Figure 1B), were higher by 33.5%, 31.3% for insulin (Figure 1C), and were higher by 98.6%, 177.4% for HOMA-β (Figure 1D), respectively.